BIOMAT Database Logo BIOMAT Database Logo

Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas. 1979

M Bayssas, and J Gouveia, and P Ribaud, and M Musset, and F de Vassal, and J L Pico, and L de Luca, and J L Misset, and D Machover, and D Belpomme, and L Schwarzenberg, and C Jasmin, and M Hayat, and G Mathé

Vindesine (VDS) has been submitted to a phase-II trial, the results of which were assessed in terms of regression induction. VDS was given weekly IV in doses of 2 mg/m2 on two consecutive days to 59 patients, 55 of whom were evaluable. A high proportion of complete (36%) and over 50% partial regressions were obtained in acute lymphoid leukemias (ALL) (overall response 63%) whatever the perceptible phase, in blastic crisis of chronic myeloid luekemia (55%), and some responses were recorded in lymphosarcoma (40%). No effect has so far been seen in acute myeloid keukemia or in Hodgkin's disease. Malignant neoplasms of the immunoblastic type seem to be particularly sensitive to VDS. Continuous 48 h IV infusion can induce a remission where an IV push administration of the same dose has failed. One remarkable characteristic of VDS is the apparent absence of cross-resistance with VCR: in acute leukemic forms, 55% of patients who failed to obtain remission induction after three weekly injections of VCR (used in combination chemotherapy) achieved a complete or partial remission with VDS. The toxicity was mainly neurologic (paralytic ileus, constipation, paresthesias, loss of reflexes) and hematologic (leukopenia and thrombopenia), and was not more significant than with the other agents: four patients died of infection or hemorrhage.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D008228 Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. Non-Hodgkin Lymphoma,Diffuse Mixed Small and Large Cell Lymphoma,Diffuse Mixed-Cell Lymphoma,Diffuse Small Cleaved-Cell Lymphoma,Diffuse Undifferentiated Lymphoma,Lymphatic Sarcoma,Lymphoma, Atypical Diffuse Small Lymphoid,Lymphoma, Diffuse,Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic,Lymphoma, High-Grade,Lymphoma, Intermediate-Grade,Lymphoma, Low-Grade,Lymphoma, Mixed,Lymphoma, Mixed Cell, Diffuse,Lymphoma, Mixed Lymphocytic-Histiocytic,Lymphoma, Mixed Small and Large Cell, Diffuse,Lymphoma, Mixed-Cell,Lymphoma, Mixed-Cell, Diffuse,Lymphoma, Non-Hodgkin's,Lymphoma, Non-Hodgkin, Familial,Lymphoma, Non-Hodgkins,Lymphoma, Nonhodgkin's,Lymphoma, Nonhodgkins,Lymphoma, Pleomorphic,Lymphoma, Small Cleaved Cell, Diffuse,Lymphoma, Small Cleaved-Cell, Diffuse,Lymphoma, Small Non-Cleaved-Cell,Lymphoma, Small Noncleaved-Cell,Lymphoma, Small and Large Cleaved-Cell, Diffuse,Lymphoma, Undifferentiated,Lymphoma, Undifferentiated, Diffuse,Lymphosarcoma,Mixed Small and Large Cell Lymphoma, Diffuse,Mixed-Cell Lymphoma,Mixed-Cell Lymphoma, Diffuse,Non-Hodgkin's Lymphoma,Reticulosarcoma,Reticulum Cell Sarcoma,Reticulum-Cell Sarcoma,Sarcoma, Lymphatic,Sarcoma, Reticulum-Cell,Small Cleaved-Cell Lymphoma, Diffuse,Small Non-Cleaved-Cell Lymphoma,Small Noncleaved-Cell Lymphoma,Undifferentiated Lymphoma,Diffuse Lymphoma,Diffuse Lymphomas,Diffuse Mixed Cell Lymphoma,Diffuse Mixed-Cell Lymphomas,Diffuse Small Cleaved Cell Lymphoma,Diffuse Undifferentiated Lymphomas,High-Grade Lymphoma,High-Grade Lymphomas,Intermediate-Grade Lymphoma,Intermediate-Grade Lymphomas,Low-Grade Lymphoma,Low-Grade Lymphomas,Lymphatic Sarcomas,Lymphocytic-Histiocytic Lymphoma, Mixed,Lymphocytic-Histiocytic Lymphomas, Mixed,Lymphoma, Diffuse Mixed-Cell,Lymphoma, Diffuse Undifferentiated,Lymphoma, High Grade,Lymphoma, Intermediate Grade,Lymphoma, Low Grade,Lymphoma, Mixed Cell,Lymphoma, Mixed Lymphocytic Histiocytic,Lymphoma, Non Hodgkin,Lymphoma, Non Hodgkin's,Lymphoma, Non Hodgkins,Lymphoma, Nonhodgkin,Lymphoma, Small Non Cleaved Cell,Lymphoma, Small Noncleaved Cell,Lymphosarcomas,Mixed Cell Lymphoma,Mixed Cell Lymphoma, Diffuse,Mixed Lymphocytic-Histiocytic Lymphoma,Mixed Lymphocytic-Histiocytic Lymphomas,Mixed Lymphoma,Mixed Lymphomas,Mixed-Cell Lymphomas,Non Hodgkin Lymphoma,Non Hodgkin's Lymphoma,Non-Cleaved-Cell Lymphoma, Small,Non-Hodgkins Lymphoma,Noncleaved-Cell Lymphoma, Small,Nonhodgkin's Lymphoma,Nonhodgkins Lymphoma,Pleomorphic Lymphoma,Pleomorphic Lymphomas,Reticulosarcomas,Reticulum Cell Sarcomas,Reticulum-Cell Sarcomas,Sarcoma, Reticulum Cell,Small Cleaved Cell Lymphoma, Diffuse,Small Non Cleaved Cell Lymphoma,Small Non-Cleaved-Cell Lymphomas,Small Noncleaved Cell Lymphoma,Small Noncleaved-Cell Lymphomas,Undifferentiated Lymphoma, Diffuse,Undifferentiated Lymphomas
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females

Related Publications

M Bayssas, and J Gouveia, and P Ribaud, and M Musset, and F de Vassal, and J L Pico, and L de Luca, and J L Misset, and D Machover, and D Belpomme, and L Schwarzenberg, and C Jasmin, and M Hayat, and G Mathé
Phase II trial of vindesine in patients with malignant melanoma.
January 1980, Cancer treatment reports,
M Bayssas, and J Gouveia, and P Ribaud, and M Musset, and F de Vassal, and J L Pico, and L de Luca, and J L Misset, and D Machover, and D Belpomme, and L Schwarzenberg, and C Jasmin, and M Hayat, and G Mathé
Phase II trial of vindesine in patients with acute leukemia.
January 1979, Cancer treatment reports,
M Bayssas, and J Gouveia, and P Ribaud, and M Musset, and F de Vassal, and J L Pico, and L de Luca, and J L Misset, and D Machover, and D Belpomme, and L Schwarzenberg, and C Jasmin, and M Hayat, and G Mathé
Phase II trial of vindesine in patients with malignant lymphoma.
May 1979, Cancer treatment reports,
M Bayssas, and J Gouveia, and P Ribaud, and M Musset, and F de Vassal, and J L Pico, and L de Luca, and J L Misset, and D Machover, and D Belpomme, and L Schwarzenberg, and C Jasmin, and M Hayat, and G Mathé
Phase II trial of vindesine in patients with germ-cell tumors.
August 1979, Cancer treatment reports,
M Bayssas, and J Gouveia, and P Ribaud, and M Musset, and F de Vassal, and J L Pico, and L de Luca, and J L Misset, and D Machover, and D Belpomme, and L Schwarzenberg, and C Jasmin, and M Hayat, and G Mathé
Vindesine. A phase II trial in advanced breast cancer patients.
January 1981, Cancer clinical trials,
M Bayssas, and J Gouveia, and P Ribaud, and M Musset, and F de Vassal, and J L Pico, and L de Luca, and J L Misset, and D Machover, and D Belpomme, and L Schwarzenberg, and C Jasmin, and M Hayat, and G Mathé
Phase II trial of vindesine in patients with small cell lung carcinoma.
January 1981, Cancer treatment reports,
M Bayssas, and J Gouveia, and P Ribaud, and M Musset, and F de Vassal, and J L Pico, and L de Luca, and J L Misset, and D Machover, and D Belpomme, and L Schwarzenberg, and C Jasmin, and M Hayat, and G Mathé
Vindesine for metastatic malignant melanoma. A phase II trial.
October 1983, American journal of clinical oncology,
M Bayssas, and J Gouveia, and P Ribaud, and M Musset, and F de Vassal, and J L Pico, and L de Luca, and J L Misset, and D Machover, and D Belpomme, and L Schwarzenberg, and C Jasmin, and M Hayat, and G Mathé
Vindesine in bronchogenic carcinoma: a phase II trial.
February 1982, American journal of clinical oncology,
M Bayssas, and J Gouveia, and P Ribaud, and M Musset, and F de Vassal, and J L Pico, and L de Luca, and J L Misset, and D Machover, and D Belpomme, and L Schwarzenberg, and C Jasmin, and M Hayat, and G Mathé
Phase II trial of TCNU and vindesine in patients with adenocarcinoma of the lung.
April 1990, European journal of cancer (Oxford, England : 1990),
M Bayssas, and J Gouveia, and P Ribaud, and M Musset, and F de Vassal, and J L Pico, and L de Luca, and J L Misset, and D Machover, and D Belpomme, and L Schwarzenberg, and C Jasmin, and M Hayat, and G Mathé
[Phase II therapeutic trial (screening) of ifosfamide in hematosarcomas and solid tumors].
January 1975, Semaine des hopitaux. Therapeutique,
Copied contents to your clipboard!